Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Pacira BioSciences, Inc. Common Stock

PCRX

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $0.00 – $0.00
Volume 0
Market cap $1.46B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$1.46B
Price / earnings
38.59×
Price / book
2.04×
Price / sales
1.96×
EV / sales
2.02×
EV / EBITDA
12.63×

Profitability

Earnings per share
$0.95
Return on assets
3.14%
Return on equity
5.3%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.41×
Current ratio
4.68×
Quick ratio
3.65×
Cash ratio
1.96×

Cash flow

Price / cash flow
8.23×
Price / free cash flow
8.62×
Free cash flow
$169M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for PCRX, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$176.65M$192.4M$177.38M$196.87M$179.52M$181.1M$168.92M$187.25M
Cost of revenue$37.23M$44.16M$36.41M$40.3M$34.28M$40.87M$34.31M$39.89M
Gross profit$139.42M$148.24M$140.96M$156.57M$145.24M$140.23M$134.62M$147.37M
Selling, general and administrative$83.84M$91.81M$93.94M$101.61M$91.8M$88.58M$86.78M$79.61M
Research and development$26.68M$30.24M$28.07M$37.45M$25.97M$28.2M$25.34M$23.9M
Total operating expenses$117.15M$143.97M$134.06M$154.23M$138.88M$131.73M$132.63M$122.66M
Operating income$22.27M$4.27M$6.9M$2.34M$6.36M$8.5M$1.99M$24.7M
Interest expense-$2.89M-$3.62M-$3.7M-$3.89M-$4.28M-$4.7M-$4.58M-$4.68M
Income before taxes$28.81M$2.56M$5M$571K$9.52M-$1.93M$8.71M$25.53M
Income taxes$293K-$2.1M$2.08M-$1.07M$4.09M$2.92M$3.89M$9.49M
Net income$28.52M$4.65M$2.92M$1.64M$5.43M-$4.85M$4.81M$16.04M
Net income attributable to common shareholders$28.52M$4.65M$2.92M$1.64M$5.43M-$4.85M$4.81M$16.04M
EBITDA$40.88M$26.23M$28.23M$23.68M$27.37M$36.01M$23.16M$45.95M
Basic earnings per share$0.72$0.12$0.07$0.04$0.12-$0.11$0.10$0.35
Diluted earnings per share$0.70$0.12$0.07$0.04$0.12-$0.11$0.10$0.44

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Harrow (HROW) Expected to Beat Earnings Estimates: Should You Buy?

Harrow (HROW) is expected to report Q3 2026 earnings on November 9 with a consensus EPS estimate of $0.17 (down 48.5% YoY) but revenues of $99.88M (up 39.4% YoY). With a +44.00% Earnings ESP and Zacks Rank #3, analysts predict the company will likely beat consensus estimates. Pacira BioSciences (PCRX) is also expected to beat estimates with a +0.87% Earnings ESP and Zacks Rank #3.

Zacks Investment Research

Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio

Viatris (VTRS) has agreed to acquire Pacira BioSciences (PCRX) for $1.65 billion in cash at $36.50 per share, expected to close by end of 2026. The acquisition adds two marketed pain therapies (Exparel and Zilretta) generating $350.5 million in H1 2026 sales, plus a mid-stage gene therapy candidate (PCRX-201) for knee osteoarthritis. The deal is expected to be immediately accretive to Viatris' financial metrics and strengthen its non-opioid pain management portfolio.

The Motley Fool

Why Pacira BioSciences Skyrocketed Today

Pacira BioSciences surged 44% after announcing its acquisition by Viatris for $36.50 per share, valuing the company at approximately $1.65 billion. The deal represents a 45% premium to the previous closing price and is expected to close by end of 2026. Viatris plans to leverage Pacira's non-opioid pain management products, including Exparel and Zilretta, to strengthen its innovative medicines business.

Zacks Investment Research

PCRX Expands Exparel Commercial Reach in Europe Through Molteni Deal

Pacira BioSciences announced an exclusive agreement with Italian pharmaceutical company Molteni Farmaceutici to distribute and commercialize Exparel across the EU and UK. Molteni will launch the long-acting local anesthetic in Italy, Germany, Austria, and Poland starting in 2027, while Pacira retains manufacturing rights and will receive upfront payments, supply fees, and royalties. The deal supports Pacira's international expansion strategy while the company advances other pain management products including Zilretta and PCRX-201.

Zacks Investment Research

Pacira (PCRX) Up 6.9% Since Last Earnings Report: Can It Continue?

Pacira (PCRX) reported Q2 2026 adjusted earnings of 73 cents per share, beating consensus estimates of 64 cents, with revenues of $192.4 million exceeding expectations. However, the company lowered its 2026 total revenue guidance to $735-$760 million from $745-$770 million following the divestiture of iovera to Zimmer Biomet. Despite the earnings beat, estimates have been trending downward, and the stock received a Zacks Rank #3 (Hold) rating with expectations for in-line returns.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.